Ratings by Roth/MKM (Adam Walsh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/27/2026 | BioAge Labs Inc | BIOA | New Coverage | Buy (N/A) |
16.61 (21.47) |
29.26% | Details | |
| 4/2/2026 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Buy) |
40.23 (40.23) |
0% | Details | |
| 4/2/2026 | Apellis Pharmaceuticals | APLS | Downgrade | Neutral (Buy) |
40.23 (41.03) |
1.99% | Details | |
| 3/13/2026 | Equillium | EQ | New Coverage | Buy (N/A) |
1.99 (2.86) |
43.72% | Details | |
| 3/13/2026 | Apellis Pharmaceuticals | APLS | New Coverage | Buy (N/A) |
19.38 (19.38) |
0% | Details | |
| 3/13/2026 | Apellis Pharmaceuticals | APLS | New Coverage | Buy (N/A) |
19.38 (19.38) |
0% | Details | |
| 3/13/2026 | Apellis Pharmaceuticals | APLS | New Coverage | Buy (N/A) |
19.38 (40.23) |
107.59% | Details | |
| 1/23/2026 | Insmed | INSM | New Coverage | Buy (N/A) |
156.32 (98.61) |
-36.92% | Details | |
| 1/23/2026 | vTv Therapeutics | VTVT | New Coverage | Buy (N/A) |
33.05 (33.92) |
2.63% | Details |
